key: cord-0895676-ivh3vv7q
authors: Nishizawa, Toshinori; Jinta, Torahiko; Koyamada, Ryosuke; Uehara, Yuki; Taki, Fumika; Arioka, Hiroko
title: Adverse reactions of BNT162b2 vaccine booster against COVID‐19 in Japan
date: 2022-04-06
journal: J Gen Fam Med
DOI: 10.1002/jgf2.545
sha: 218b47d415655c6c29609bfa62c574c43b461f08
doc_id: 895676
cord_uid: ivh3vv7q

Female participants had a higher incidence of headache, nausea, myalgia, arthralgia, redness, pruritus, and inoculation site redness and pruritus (p 0.05). Low grade fever, headache, malaise, myalgia, and inoculation site induration and heat were associated with age group (p 0.05).

To the Editor, On December 3, 2021, the administration of the third dose of the and other countries has already proven its efficacy and short-term safety; however, the adverse reactions in Japanese people after the third dose of the vaccine were unknown. 1 The age distribution was as follows: 19.8% of participants were in their 20s, 28.2% in 30s, 28.2% in 40s, 18.3% in 50s, and 5.6% in 60s.

After the third dose, 646 participants (99.5%) experienced some adverse reaction, regardless of gender and age. Adverse reactions included high-grade fever (≧38°C, 21.6%), low-grade fever (37.0°C-37.9°C, 54.9%), headache (59.3%), malaise (78.2%), nasal discharge (6.2%), nausea (13.7%), vomiting (1.9%), diarrhea (7.1%), chills (49.5%), myalgia (61.3%), and arthralgia (42.8%) and pain (92.3%), redness (16.6%), swelling (25.7%), induration (10.0%), pruritus (15.0%), and heat (32.2%) at the inoculation site. Female participants had a higher incidence of headache, nausea, myalgia, arthralgia, redness, pruritus, and inoculation site redness and pruritus (p < 0.05, Table 1 ).

High-grade fever, headache, malaise, and myalgia were reported significantly more frequently in the younger age groups (p < 0.05, 

Protection of BNT162b2 vaccine booster against Covid-19 in Israel

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months

Side effects and antibody titer transition of the BNT162b2 messenger ribonucleic acid coronavirus disease 2019 vaccine in Japan

The authors wish to thank Shiori Tomita, MD, MPH, St. Luke's International Hospital, for statistical support.